EXPANDED ACCESS POLICY OF SANBEXIN SUBLINGUAL TABLETS IN THE US

Expanded Access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational drug for treatment outside of a clinical trial when no comparable or satisfactory alternative therapy exists.

As a general policy, Simcere will not provide Sanbexin SL on Expanded Access at this time anywhere in the world. Simcere believes that participation in our clinical trial program is the most appropriate way to access our investigational therapy. Simcere will continue to assess the eligibility requirements and criteria for Early Access and will re-evaluate this policy from time to time.